504 related articles for article (PubMed ID: 19359287)
1. Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia.
Melani A; Cipriani S; Vannucchi MG; Nosi D; Donati C; Bruni P; Giovannini MG; Pedata F
Brain; 2009 Jun; 132(Pt 6):1480-95. PubMed ID: 19359287
[TBL] [Abstract][Full Text] [Related]
2. The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia.
Melani A; Gianfriddo M; Vannucchi MG; Cipriani S; Baraldi PG; Giovannini MG; Pedata F
Brain Res; 2006 Feb; 1073-1074():470-80. PubMed ID: 16443200
[TBL] [Abstract][Full Text] [Related]
3. The selective adenosine A2A receptor agonist CGS 21680 reduces JNK MAPK activation in oligodendrocytes in injured spinal cord.
Genovese T; Melani A; Esposito E; Mazzon E; Di Paola R; Bramanti P; Pedata F; Cuzzocrea S
Shock; 2009 Dec; 32(6):578-85. PubMed ID: 19295488
[TBL] [Abstract][Full Text] [Related]
4. Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes.
Brambilla R; Cottini L; Fumagalli M; Ceruti S; Abbracchio MP
Glia; 2003 Aug; 43(2):190-4. PubMed ID: 12838511
[TBL] [Abstract][Full Text] [Related]
5. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow.
Gianfriddo M; Melani A; Turchi D; Giovannini MG; Pedata F
Neurobiol Dis; 2004 Oct; 17(1):77-88. PubMed ID: 15350968
[TBL] [Abstract][Full Text] [Related]
6. Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice.
Cipriani S; Bizzoco E; Gianfriddo M; Melani A; Vannucchi MG; Pedata F
Exp Neurol; 2008 Sep; 213(1):163-70. PubMed ID: 18586241
[TBL] [Abstract][Full Text] [Related]
7. Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum.
Tebano MT; Pintor A; Frank C; Domenici MR; Martire A; Pepponi R; Potenza RL; Grieco R; Popoli P
J Neurosci Res; 2004 Jul; 77(1):100-7. PubMed ID: 15197743
[TBL] [Abstract][Full Text] [Related]
8. Differential early mitogen-activated protein kinase activation in hyperglycemic ischemic brain injury in the rat.
Farrokhnia N; Roos MW; Terént A; Lennmyr F
Eur J Clin Invest; 2005 Jul; 35(7):457-63. PubMed ID: 16008548
[TBL] [Abstract][Full Text] [Related]
9. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
[TBL] [Abstract][Full Text] [Related]
10. Adenosine A 2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors.
Pintor A; Galluzzo M; Grieco R; Pèzzola A; Reggio R; Popoli P
J Neurochem; 2004 Apr; 89(1):152-6. PubMed ID: 15030399
[TBL] [Abstract][Full Text] [Related]
11. Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration.
Minghetti L; Greco A; Potenza RL; Pezzola A; Blum D; Bantubungi K; Popoli P
J Neuropathol Exp Neurol; 2007 May; 66(5):363-71. PubMed ID: 17483693
[TBL] [Abstract][Full Text] [Related]
12. The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat.
Melani A; Pantoni L; Bordoni F; Gianfriddo M; Bianchi L; Vannucchi MG; Bertorelli R; Monopoli A; Pedata F
Brain Res; 2003 Jan; 959(2):243-50. PubMed ID: 12493612
[TBL] [Abstract][Full Text] [Related]
13. Glial cell line-derived neurotrophic factor (GDNF) enhances dopamine release from striatal nerve endings in an adenosine A2A receptor-dependent manner.
Gomes CA; Vaz SH; Ribeiro JA; Sebastião AM
Brain Res; 2006 Oct; 1113(1):129-36. PubMed ID: 16935271
[TBL] [Abstract][Full Text] [Related]
14. Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat.
Rebola N; Canas PM; Oliveira CR; Cunha RA
Neuroscience; 2005; 132(4):893-903. PubMed ID: 15857695
[TBL] [Abstract][Full Text] [Related]
15. Low doses of the selective adenosine A2A receptor agonist CGS21680 are protective in a rat model of transient cerebral ischemia.
Melani A; Corti F; Cellai L; Vannucchi MG; Pedata F
Brain Res; 2014 Mar; 1551():59-72. PubMed ID: 24457041
[TBL] [Abstract][Full Text] [Related]
16. Effects of hyperglycemic and normoglycemic cerebral ischemia on phosphorylation of c-jun NH2-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK).
He QP; Ding C; Li PA
Cell Mol Biol (Noisy-le-grand); 2003 Dec; 49(8):1241-7. PubMed ID: 14983993
[TBL] [Abstract][Full Text] [Related]
17. Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801.
Cunha GM; Canas PM; Melo CS; Hockemeyer J; Müller CE; Oliveira CR; Cunha RA
Exp Neurol; 2008 Apr; 210(2):776-81. PubMed ID: 18191838
[TBL] [Abstract][Full Text] [Related]
18. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.
Tanganelli S; Sandager Nielsen K; Ferraro L; Antonelli T; Kehr J; Franco R; Ferré S; Agnati LF; Fuxe K; Scheel-Krüger J
Parkinsonism Relat Disord; 2004 Jul; 10(5):273-80. PubMed ID: 15196505
[TBL] [Abstract][Full Text] [Related]
19. Behavioural and neurochemical characterization of the adenosine A2A receptor antagonist ST1535.
Galluzzo M; Pintor A; Pèzzola A; Grieco R; Borsini F; Popoli P
Eur J Pharmacol; 2008 Jan; 579(1-3):149-52. PubMed ID: 18036583
[TBL] [Abstract][Full Text] [Related]
20. Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice.
Dall'Igna OP; Fett P; Gomes MW; Souza DO; Cunha RA; Lara DR
Exp Neurol; 2007 Jan; 203(1):241-5. PubMed ID: 17007839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
